Target Information
Target General Infomation | Top | ||||
---|---|---|---|---|---|
Target ID |
T87374
|
||||
Target Name |
COVID-19 spike glycoprotein (S)
|
||||
Synonyms |
COVID-19 S glycoprotein; COVID-19 E2; COVID-19 Peplomer protein
|
||||
Gene Name |
COVID-19 S
|
||||
Target Status |
Target in Phase 2 Trial
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | COVID-19 [ICD-11: 1D6Y] | ||||
Function |
Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
|
||||
BioChemical Class |
Betacoronaviruses spike protein family
|
||||
UniProt ID |
Drugs and Modes of Action | Top | ||||
---|---|---|---|---|---|
Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
1 | Nafamostat | Drug Info | Phase 2 Trial | COVID-19 | [2] |
Investigative agents | [+] 1 Investigative agents | + | |||
1 | Toremifene | Drug Info | Investigative | COVID-19 | [3] |
Mode of Action | [+] 1 Modes of Action | + | |||
Inhibitor | [+] 2 Inhibitor drugs | + | |||
1 | Nafamostat | Drug Info | [1] | ||
2 | Toremifene | Drug Info | [3] |
References | Top | ||||
---|---|---|---|---|---|
1 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | ||||
2 | ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health. | ||||
3 | Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.